Polypharmacy and Major Adverse Events in Atrial Fibrillation.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 12 2022
01 12 2022
Historique:
received:
25
03
2022
accepted:
02
07
2022
pubmed:
4
8
2022
medline:
15
12
2022
entrez:
3
8
2022
Statut:
epublish
Résumé
Patients with atrial fibrillation (AF) often receive multiple medications daily. The purpose of this study was to examine the prognostic implications of polypharmacy in patients with AF. This is a retrospective post hoc analysis of 1113 AF patients, enrolled in a randomized trial during an acute hospitalization (MISOAC-AF, NCT02941978). The presence of polypharmacy (use of >4 drugs daily) was assessed at hospital discharge. Regression analyses were performed to identify clinical predictors of polypharmacy and compare the outcomes of patients with or without confirmed polypharmacy. The coprimary outcomes were all-cause and cardiovascular (CV) mortality. Among patients with polypharmacy, the difference in the risk of mortality was also assessed per each added drug as a numeric variable. Polypharmacy was found in 36.9% of participants. Dyslipidemia, coronary artery disease, lower left ventricular ejection fraction, and higher glomerular filtration rates were independent predictors of polypharmacy. Polypharmacy was an independent predictor for all-cause death (adjusted hazard ratio [aHR]: 1.29, 95% confidence interval [CI]: 1.01-1.64) and CV death (aHR: 1.39, 95% CI: 1.05-1.84). Among patients with polypharmacy, each additional concomitant medication was independently associated with a 4% increased risk of all-cause mortality (aHR = 1.04, 95% CI: 1.00-1.08) and a 5% increased risk of CV mortality (aHR = 1.05, 95% CI: 1.00-1.10). Polypharmacy was common among patients with AF hospitalized in a tertiary hospital and was incrementally associated with higher rates of mortality.
Identifiants
pubmed: 35921643
doi: 10.1097/FJC.0000000000001339
pii: 00005344-202212000-00010
doi:
Banques de données
ClinicalTrials.gov
['NCT02941978', 'NCT02941978']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
826-831Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230.
Walckiers D, Van der Heyden J, Tafforeau J. Factors associated with excessive polypharmacy in older people. Arch Public Health. 2015;73:50.
Kornej J, Börschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127:4–20.
Quinn KJ, Shah NH. A dataset quantifying polypharmacy in the United States. Scientific Data. 2017;4:170167.
Eggebrecht L, Nagler M, Göbel S, et al. Relevance of polypharmacy for clinical outcome in patients receiving vitamin K antagonists. J Am Geriatr Soc. 2019;67:463–470.
Ling L-H, Kistler PM, Kalman JM, et al. Comorbidity of atrial fibrillation and heart failure. Nat Rev Cardiol. 2016;13:131–147.
Samaras A, Vrana E, Kartas A, et al. Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2021;21:453.
Papazoglou ASKA, Kartas A, Samaras A, et al. Prognostic significance of diabetes mellitus in patients with atrial fibrillation. Cardiovasc Diabetol. 2021;20:40.
Shaikh F, Pasch LB, Newton PJ, et al. Addressing multimorbidity and polypharmacy in individuals with atrial fibrillation. Curr Cardiol Rep. 2018;20:32.
Gallagher C, Nyfort-Hansen K, Rowett D, et al. Polypharmacy and health outcomes in atrial fibrillation: a systematic review and meta-analysis. Open Heart. 2020;7:e001257.
Tzikas A, SAmArAs A, KArtAs A, et al. Motivational interviewing to Support oral AntiCoagulation adherence in patients with non-valvular atrial fibrillation (MISOAC-AF): a randomised clinical trial. Eur Heart J Cardiovasc Pharmacother. 2021;7:f63–f71.
Samaras A, KArtAs A, VasDeki D, et al. Rationale and design of a randomized study comparing motivational interviewing to Support oral AntiCoagulation adherence versus usual care in patients with non-valvular atrial fibrillation: the MISOAC-AF trial. Hellenic J Cardiol. 2020;61:453–454.
World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–2194.
Proietti M, Raparelli V, Olshansky B, Lip GYH. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016;105:412–420.
Raparelli V, Proietti M, Buttà C, et al. Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study. Intern Emerg Med. 2014;9:861–870.
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardio-Thoracic Surg. 20162016;50:e1–e88.
Jaspers Focks J, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868.
Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133:352–360.
Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22:597–602.
Martinez BK, Baker WL, Sood NA, et al. Influence of polypharmacy on the effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation. Pharmacotherapy. 2019;39:196–203.
Steinberg BA, Kim S, Piccini JP, et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013;128:721–728.
Caturano A, Brunelli V, Galiero R, et al. Comment on: warfarin adherence and anticoagulation control in atrial fibrillation patients–a systematic review. Eur Rev Med Pharmacol Sci. 2022;26:1068–1069.
Rochon PA, Petrovic M, Cherubini A, et al. Polypharmacy, inappropriate prescribing, and deprescribing in older people: through a sex and gender lens. The Lancet Healthy Longevity. 2021;2:e290–e300.
Sasso FC, Pafundi PC, Simeon V, et al. Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease. Cardiovasc Diabetology. 2021;20:145.
Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827–834.